Page last updated: 2024-09-05

sorafenib and hypothemycin

sorafenib has been researched along with hypothemycin in 1 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(hypothemycin)
Trials
(hypothemycin)
Recent Studies (post-2010) (hypothemycin)
6,5207305,25135018

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)hypothemycin (IC50)
Mitogen-activated protein kinase kinase kinase 7Homo sapiens (human)0.033
Nuclear receptor subfamily 2 group C member 2Homo sapiens (human)0.03
Glycogen synthase kinase-3 betaHomo sapiens (human)0.663
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1Homo sapiens (human)0.03

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bensinger, D; Cremer, A; Engemann, V; Kohl, V; Schmidt, B; Schmitz, K; Stegmaier, K; Stubba, D; Stuckert, J; Waßmer, T1

Other Studies

1 other study(ies) available for sorafenib and hypothemycin

ArticleYear
Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.
    Journal of medicinal chemistry, 2019, 03-14, Volume: 62, Issue:5

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cell Line, Tumor; Embryo, Nonmammalian; fms-Like Tyrosine Kinase 3; High-Throughput Screening Assays; Humans; Molecular Docking Simulation; Mutation; Prospective Studies; Protein Kinase Inhibitors; Zebrafish

2019